Compare Church & Dwight Co., Inc. (CHD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Incyte Corporation — how do they compare? Church & Dwight Co., Inc. trades at $103.35 (market cap $24.38B), while Incyte Corporation trades at $120.61 (market cap $24.54B). The key difference: Church & Dwight Co., Inc. and Incyte Corporation are close in size by market cap, and Church & Dwight Co., Inc. pays a 1.2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CHD | INCY | |
|---|---|---|
Market Cap | $24.38B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $129.93 |
52-Week Low | $81.60 | $81.61 |
Enterprise Value | $26.38B | $20.04B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $103.30, up 0.06% today, near its consensus price target of $103.57. The stock shows bullish technical signals with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Recent news highlights volume-driven performance and market share gains.
The outlook remains positive given raised earnings guidance and consistent dividend payments, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with 53% buy ratings, supporting a stable investment case for long-term growth in the consumer staples sector.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
